IHC Services

Deliver robust IHC biomarker data for oncology & immuno-oncology translational programs.

TriStar offers a wide range of established oncology and immuno-oncology IHC assays optimized and conducted on automated platforms to deliver robust biomarker results.

TriStar’s experienced IHC scientists and qualified pathologists routinely develop and optimize IHC assays for novel biomarkers, from selection of suitable antibodies through to optimal pathologist/image analysis solutions, including bespoke IHC assay transfers.

Benefits of choosing Tristar’s services

Automated IHC Platforms

Reproducible IHC biomarker data utilizing automated IHC platforms (Ventana, Dako).

Digital Pathology Services

TriStar utilizes open source image analysis solutions (QuPath & CellProfiler) in addition to Indica Labs Halo image analysis platform.

4MD Pathologists

TriStar pathologists can deliver IHC biomarker scores to customer-agreed criteria, including pathologist-assisted digital image analysis outputs.

Scientifically Relevant TMAs

Targeted TMA collection with extensive molecular & clinical follow up information, including multi-tumor or tumor-specific TMAs for most solid tumor and heme malignancies. Multi-normal (non-malignant) tissue TMAs to benchmark tumor specific biomarker expression.

Service Workflow

Define Your Project Requirements
We will sit down with you and work out exactly what the objective of your project is as well as the parameters to work within.
Sample Allocation
We will source the right samples from within our repositories and network.
Services Platform
We will make sure we can put together the right team and platforms to complete your project correctly and on time.
Confirm & Start Project
A Statement of Work that includes a project plan, deliverables, costs and timelines will be discussed and agreed upon.

A Skilled Team to Expedite Your Biomarker Research

Related Services


Association of immune microenvironment to response in treatment naïve non-small cell lung cancer (NSCLC) samples with follow-up second line immunotherapy data

The Mediterranean Institute of Oncology, Catania, Italy04/04/2020

Opposing CD68/CD163 tumor immune microenvironments revealed using a large multi-tumor tissue microarray (TMA) comprising cores from invasive margin (IM) and tumor center (TC)